secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001213900-24-033471
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals terminates CMO Dr. Bankole A. Johnson, effective May 17, 2024
--------------------------------------------------------------------------------

- Company provided notice to Dr. Johnson on April 10, 2024, terminating consulting agreement.
- Termination effective May 17, 2024; Dr. Johnson will no longer serve as Chief Medical Officer.
- No successor or replacement Chief Medical Officer announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024033471/0001213900-24-033471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024033471/ea020390801-8k_adialpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-033471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer